Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Augmentation in Treatment-Resistant Depression
NCT00174577Phase 3Unknown
- Sponsor
- Rhode Island Hospital
- Start
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Risperidone Augmentation with Placebo Augmentation (2 arms). Primary endpoints: Montgomery-Asberg Depression Rating Scale at 4 weeks, Remission Rate at 4 weeks and 2 more. Status: unknown.
02
Drugs
risperidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00174577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174577.